## Akitake Mukasa

***Japan***

Prof Akitake Mukasa, M.D., Ph.D., is a Professor of Neurosurgery at Department of Neurosurgery, Graduate School of Medical Sciences, Kumamoto University. He completed his undergraduate training and PhD at Tokyo University. He has held appointments at the Fuji Brain Institute, Showa General Hospital, the Genome Science Division at the University of Tokyo, the Ludwig Institute for Cancer Research in San Diego and the Department of Neurosurgery at the University of Tokyo. He has held various roles in Japanese & international physician associations, including in the Japanese Cancer Association (JCA). He has special interests in Neuro-Oncology, especially in the treatment of malignant brain tumors, molecular genetics & biology of brain tumors, molecular targeted therapy and individualised therapy, image-guided surgery and awake surgery. He has published widely, with a special focus on molecular aspects of neuro-oncology.

**Topic: Tumor Treating Fields in GBM – Evidence and Experience: Systematic Review / Meta Analysis and Case Report**

Glioblastoma multiforme (GBM) is a devastating disease with poor prognosis. Optune, a portable device that administers Tumor Treating Fields (TTFields), is the first therapy in over a decade to demonstrate a clinically and statistically significant improvement in overall survival in newly diagnosed GBM patients when added to temozolomide. As part of a NCCN Category 1 Preferred regimen in the NCCN Guidelines, Optune is an important tool in a physician's armamentarium in the management of GBM. Optune is now available in Singapore.

In this symposium, our esteemed faculty share and discuss the published scientific and clinical data behind this unique treatment modality, as well as insights into their personal and institutional experience with Optune.